BR9916894A - ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek - Google Patents
ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mekInfo
- Publication number
- BR9916894A BR9916894A BR9916894-4A BR9916894A BR9916894A BR 9916894 A BR9916894 A BR 9916894A BR 9916894 A BR9916894 A BR 9916894A BR 9916894 A BR9916894 A BR 9916894A
- Authority
- BR
- Brazil
- Prior art keywords
- sulfohydroxamates
- mek inhibitors
- sulfohydroxamic
- sulfohydroxamic acids
- acids
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
- C07C311/39—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
Abstract
Patente de Invenção: "áCIDOS SULFOHIDROXâMICOS ESULFOHIDRO-XAMATOS E SEU USO COMO INIBIDORES DEMEK". Diarilaminas de ácido sulfohidroxâmico da fórmula (1), cujasvariáveis são conforme descrito nas reivindicações, são inibidoresde MEK e são eficazes no tratamento de doenças proliferativas,câncer, derrame, parada cardíaca, rejeição a xenoenxerto, artrite,fibrose cística, hepatomegalia, cardiomegalia, mal de Alzheimer,complicações de diabetes, septicemia e infecção viral.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11565299P | 1999-01-13 | 1999-01-13 | |
US12241799P | 1999-03-02 | 1999-03-02 | |
PCT/US1999/030417 WO2000042002A1 (en) | 1999-01-13 | 1999-12-21 | Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9916894A true BR9916894A (pt) | 2001-11-20 |
Family
ID=26813429
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9916894-4A BR9916894A (pt) | 1999-01-13 | 1999-12-21 | ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek |
Country Status (10)
Country | Link |
---|---|
US (2) | US6455582B1 (pt) |
EP (1) | EP1144372B1 (pt) |
JP (1) | JP2002534497A (pt) |
AT (1) | ATE311363T1 (pt) |
AU (1) | AU2482800A (pt) |
BR (1) | BR9916894A (pt) |
CA (1) | CA2349467A1 (pt) |
DE (1) | DE69928697T2 (pt) |
ES (1) | ES2251851T3 (pt) |
WO (1) | WO2000042002A1 (pt) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR9916894A (pt) * | 1999-01-13 | 2001-11-20 | Warner Lambert Co | ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek |
HUP0202180A3 (en) * | 1999-07-16 | 2004-10-28 | Warner Lambert Co | Method for treating chronic pain using mek inhibitors |
EP1339702A1 (en) | 2000-03-15 | 2003-09-03 | Warner-Lambert Company | 5-amide substituted diarylamines as mek inhibitors |
AU2001247372A1 (en) * | 2000-03-15 | 2001-09-24 | Warner Lambert Company | 5-amide substituted diarylamines as mex inhibitors |
WO2002017952A2 (en) | 2000-09-01 | 2002-03-07 | Van Andel Institute | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
WO2002076496A1 (en) * | 2001-03-22 | 2002-10-03 | Van Andel Institute | Anthrax lethal factor inhibits tumor growth and angiogenesis |
US7235537B2 (en) * | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
TWI343377B (en) | 2002-03-13 | 2011-06-11 | Array Biopharma Inc | N3 alkylated benzimidazole derivatives as mek inhibitors |
US7144907B2 (en) * | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
CA2542210A1 (en) | 2003-10-21 | 2005-05-06 | Warner-Lambert Company Llc | Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
US7517994B2 (en) * | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
CA2546486A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Heterocyclic inhibitors of mek and methods of use thereof |
US7732616B2 (en) * | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
JP2007512364A (ja) | 2003-11-21 | 2007-05-17 | アレイ バイオファーマ、インコーポレイテッド | Aktプロテインキナーゼインヒビター |
JP2007513967A (ja) * | 2003-12-11 | 2007-05-31 | セラヴァンス, インコーポレーテッド | 変異レセプターチロシンキナーゼが駆動する細胞増殖性疾患の処置において使用するための組成物 |
AR051248A1 (es) | 2004-10-20 | 2007-01-03 | Applied Research Systems | Derivados de 3-arilamino piridina |
UA93678C2 (ru) | 2005-05-18 | 2011-03-10 | Астразенека Аб | Гетероциклические ингибиторы mek и их применение |
WO2007049820A1 (ja) | 2005-10-28 | 2007-05-03 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物及びその用途 |
SG170737A1 (en) * | 2006-03-17 | 2011-05-30 | Univ Johns Hopkins | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
JP5116245B2 (ja) * | 2006-03-24 | 2013-01-09 | 地方独立行政法人 東京都立産業技術研究センター | 自動分析装置に用いる検量線作成用化合物 |
EP2025347A4 (en) | 2006-05-15 | 2010-08-11 | Takeda Pharmaceutical | PROPHYLACTIC AND THERAPEUTIC AGENTS AGAINST CANCER |
US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
SI2054418T1 (sl) | 2006-07-06 | 2012-02-29 | Array Biopharma Inc | Dihidrotieno pirimidini kot AKT protein kinazni inhibitorji |
EP2049546B1 (en) | 2006-07-06 | 2010-12-29 | Array Biopharma, Inc. | Dihydrofuro pyrimidines as akt protein kinase inhibitors |
US8003651B2 (en) | 2006-07-06 | 2011-08-23 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8377937B2 (en) | 2007-07-05 | 2013-02-19 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
NZ582692A (en) | 2007-07-05 | 2012-05-25 | Array Biopharma Inc | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
EP2240455B1 (en) | 2008-01-09 | 2012-12-26 | Array Biopharma, Inc. | Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor |
RU2504542C2 (ru) | 2008-01-09 | 2014-01-20 | Эррэй Биофарма Инк. | Гидроксилированные пиримидилциклопентаны в качестве ингибиторов протеинкиназы (акт) |
US8404725B2 (en) | 2008-08-04 | 2013-03-26 | Merck Patent Gmbh | Phenylamino isonicotinamide compounds |
WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
CA2777304A1 (en) | 2009-10-21 | 2011-04-28 | Marion Hitchcock | Substituted benzosulphonamides |
WO2011047795A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted benzosulphonamides |
WO2011047796A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
WO2011112678A1 (en) | 2010-03-09 | 2011-09-15 | Dana-Farber Cancer Institute, Inc. | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy |
CA2816188A1 (en) | 2010-10-29 | 2012-05-03 | Marion Hitchcock | Substituted phenoxypyridines |
EP2694073B1 (en) | 2011-04-01 | 2018-08-08 | Genentech, Inc. | Combinations of akt and mek inhibitors for treating cancer |
KR20140025434A (ko) | 2011-04-01 | 2014-03-04 | 제넨테크, 인크. | Akt 억제제 화합물 및 화학요법제의 조합물, 및 사용 방법 |
EP2714037B1 (en) | 2011-05-25 | 2016-07-13 | Université Paris Descartes | Erk inhibitors for use in treating spinal muscular atrophy |
CN103204822B (zh) | 2012-01-17 | 2014-12-03 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的苯并噁唑化合物及其制备方法和用途 |
WO2015038704A1 (en) | 2013-09-11 | 2015-03-19 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Compositions for preparing cardiomyocytes |
WO2016057367A1 (en) | 2014-10-06 | 2016-04-14 | Dana-Farber Cancer Institute, Inc. | Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response |
MA41866A (fr) | 2015-03-31 | 2018-02-06 | Massachusetts Gen Hospital | Molécules à auto-assemblage pour l'administration ciblée de médicaments |
US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
AU2020242287A1 (en) | 2019-03-21 | 2021-09-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A Dbait molecule in combination with kinase inhibitor for the treatment of cancer |
MX2022000713A (es) * | 2019-07-17 | 2022-04-27 | 2692372 Ontario Inc | Derivados de bencenosulfonamida y usos de las mismas. |
WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
GB2618680A (en) * | 2020-11-20 | 2023-11-15 | 2692372 Ontario Inc | Methods and composition for KRAS modifications |
TW202342018A (zh) | 2022-03-04 | 2023-11-01 | 美商奇奈特生物製藥公司 | Mek激酶抑制劑 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5525625A (en) | 1995-01-24 | 1996-06-11 | Warner-Lambert Company | 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders |
WO1998037881A1 (en) * | 1997-02-28 | 1998-09-03 | Warner Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
PT993439E (pt) | 1997-07-01 | 2004-12-31 | Warner Lambert Co | Derivados de acido 4-bromo ou 4-iodofenilaminobenzidroxamico e sua utilizacao como inibidores de mek |
US6310060B1 (en) | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
NL1007364C2 (nl) | 1997-10-27 | 1999-04-28 | M Van Den Brand Beheer En Bele | Werkwijze voor het toevoeren van tenminste twee fluïda aan een mengkamer, alsmede een dergelijke inrichting. |
BR9916894A (pt) * | 1999-01-13 | 2001-11-20 | Warner Lambert Co | ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek |
-
1999
- 1999-12-21 BR BR9916894-4A patent/BR9916894A/pt not_active IP Right Cessation
- 1999-12-21 CA CA002349467A patent/CA2349467A1/en not_active Abandoned
- 1999-12-21 AT AT99968151T patent/ATE311363T1/de not_active IP Right Cessation
- 1999-12-21 DE DE69928697T patent/DE69928697T2/de not_active Expired - Fee Related
- 1999-12-21 WO PCT/US1999/030417 patent/WO2000042002A1/en active IP Right Grant
- 1999-12-21 EP EP99968151A patent/EP1144372B1/en not_active Expired - Lifetime
- 1999-12-21 JP JP2000593570A patent/JP2002534497A/ja active Pending
- 1999-12-21 ES ES99968151T patent/ES2251851T3/es not_active Expired - Lifetime
- 1999-12-21 US US09/889,101 patent/US6455582B1/en not_active Expired - Fee Related
- 1999-12-21 AU AU24828/00A patent/AU2482800A/en not_active Abandoned
-
2002
- 2002-09-13 US US10/244,915 patent/US6835749B2/en not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010068738A1 (en) | 2008-12-10 | 2010-06-17 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
WO2011106298A1 (en) | 2010-02-25 | 2011-09-01 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
WO2013169858A1 (en) | 2012-05-08 | 2013-11-14 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
Also Published As
Publication number | Publication date |
---|---|
WO2000042002A1 (en) | 2000-07-20 |
EP1144372A1 (en) | 2001-10-17 |
US6455582B1 (en) | 2002-09-24 |
EP1144372B1 (en) | 2005-11-30 |
AU2482800A (en) | 2000-08-01 |
ES2251851T3 (es) | 2006-05-01 |
DE69928697T2 (de) | 2006-06-22 |
CA2349467A1 (en) | 2000-07-20 |
US6835749B2 (en) | 2004-12-28 |
JP2002534497A (ja) | 2002-10-15 |
DE69928697D1 (de) | 2006-01-05 |
US20030045521A1 (en) | 2003-03-06 |
ATE311363T1 (de) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9916894A (pt) | ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek | |
CY1119742T1 (el) | Βιολογικα συστηματα μεταφορας πολλαπλου-συστατικου | |
BR0010220A (pt) | Compostos de pirimidinona | |
EA200100773A1 (ru) | Замещенные 1-гетероциклические диариламины | |
UY26205A1 (es) | Derivados de indoloxoacetil piperazina antiviricos | |
BRPI0414799A (pt) | bifenilóxi-ácidos | |
BR0116452A (pt) | Composto, composição farmacêutica, uso de um composto | |
BRPI0515012A (pt) | substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso | |
ECSP034859A (es) | Nuevos derivados de pirrol como agentes farmacéuticos | |
AR010062A1 (es) | Nuevos benzamidaldehidos y su utilizacion | |
EA200300065A1 (ru) | Окисленные сложные эфиры 4-йодфениламинобензгидроксамовых кислот | |
ECSP045520A (es) | Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos | |
EA200300248A1 (ru) | Бициклопиразолы, активные в качестве ингибиторов киназы, способ их получения и включающие их фармацевтические композиции | |
ES2173480T3 (es) | Preparacion de derivados de ciclohexeno carboxilato. | |
ES2188979T3 (es) | Derivados de benzamidina sustituidos con derivados de aminoacidos ciclicos e hidroxiacidos ciclicos, y su uso como anti-coagulantes. | |
PT937074E (pt) | Benzonaftiridinas como terapeutica bronquica | |
AR024138A1 (es) | Inhibidores de la proliferacion celular | |
CU23047A3 (es) | Derivados de aminoacidos halogenados utiles como inhibidores de la oxido nitrico-sintasa. | |
EA200001129A3 (ru) | Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина | |
MX9801987A (es) | Nuevos derivados de aminoacido, su obtencion y su uso. | |
ATE338550T1 (de) | Mikronisierter zolpidem hemitartrat | |
BRPI0410861A (pt) | métodos e composições para a produção de aminoácidos | |
ES2187738T3 (es) | Derivados de flavonas, su procedimiento de preparacion y los compuestos farmaceuticos que las contienen. | |
PT1147103E (pt) | Fenantridina-n-oxidos com actividade inibitoria de pde-iv | |
YU16399A (sh) | ) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA(S) 8A E 9A ANUIDADE(S). |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 1986 DE 27/03/2009. |